cinogenic arylamines e.g. aminofluorene, benzidine and drugs e.g. procainamide, an anti-arrythmic agent. The initial interest in the enzyme resulted from its role in the metabolism of drugs with a hydrazine group: particularly isoniazid, an antitubercular agent. It was observed that the capacity for inactivation [ 31 of isoniazid differed among individuals. As a result of an elegant twin study, the ability to inactivate isoniazid was found to be inherited in a Mendelian fashion [4] . Inactivation of isoniazid was later equated with N-acetylation [ 5 ] and was an early example of a pharmacogenetic trait. Other compounds u hich are metabolized by arylamine NA'I' include caffeine [f) J and sulphamethazine [7] . 1Jsing these and other polymorphic substrates, it has been demonstrated repeatedly that the distribution of 'fast' and 'slow' arylamine NAT phenotypes differs in different ethnic groups (see [XI for review) . €lowever. not all arylamines are metabolized polymorphically in humans. p-Aminobenzoate and p-aminosalicylate are examples of substrates which are acetylated 'monomorphically' in humans. In addition, in different human ethnic groups the distribution of fast-and slow-acetylator individuals has been found to vary (see [8] for review).
Inbred strains of rabbits [ O ] , mice [lo] and
Abbreviations iiscd: NA'I', N-acetvltransferase; pcr, polymerase chain reaction. [ZO, 21) clones for arylamine NAT have provided information on the molecular nature of the polymorphism and have allowed identification of the enzyme responsible for monomorphic N-acetylation of arylamines in humans and in rabbits. Genes corresponding to mouse NAT have now been identified (22,23 1, as have two additional chick NATs [24] . The coding region of the different mammalian NATs are the same length (870 bases) and show over 70% identity at the nucleotide level. The least similar arylamine NATs which have been sequenced, mouse [ZZ] and chick [ 141, show 47% identity at the amino acid level. In view of the extensive sequence similarity among the different NATs it seems likely that they have all evolved from a common ancestral gene.
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Control of arylamine NAT activity appears to be exerted through two factors: (1) The number or genes and/or alleles which are present in a species or population, and (2) the tissue-specific expression of these genes.
These two aspects contribute to the differences between monomorphic and polymorphic NAl's and will be considered for mouse, rabbit and human enzymes. The contribution of these control mechanisms towards determining fast or slow NAT activity, including the ethnic differences in human NA7' polymorphism, will be presented.
Mouse
Fast-and slow-acetylating mouse strains show different levels of NA7' activity in the blood when using p-aminobenzoic acid and aminofluorene as substrates. The rate at which acetylated arylamines are detected in the urine after oral dosing of arylamines also differs between these strains [25] . On the basis of the inheritance of these traits, it was suggested that there were two separate polymorphisms in mice. From protein purification studies of NAT from mouse liver of fast-and slow-acetylating strains, it seems that protein differences in NAT from these two sources are minor [26, 271. Recently, two distinct clones from mouse genomic I)NA have been reported which are 81% identical in amino acid sequence to each other, and over 700/0 identical in amino acid sequence to human NATs 1221. These two gene loci, assigned to mouse chromosome 8 [28] , are very closely linked and have been located on the same 16 Kb fragment of mouse genomic DNA. One of these two mouse NAT genes is the same for both a fast-and a slowacetylating strain of mouse. The other NAT gene differs at only one position; there is an A to T substitution which changes amino acid 99 in the fastacetylating strain from asparagine to isoleucine in the slow-acetylating strain. From Southern blot analysis of mouse genomic I)NA there is at least one more mouse NAT gene [22.23] . A third mouse NAT gene has been identified following polymerase chain reaction (pcr) amplification of mouse genomic DNA [23], using primers designed to recognize NAT [29] . It is not yet clear which of these mouse NAT genes is expressed in mice. From estimations of the NAT content of mouse liver, it is not possible to say whether only a monomorphic NAT is expressed in slow-acetylator mouse liver, but it does seem that the number of genes present in the fast-and slow-acetylating mouse strains are likely to be the same [22, 23] . In rabbits, tissue distribution of NA7' has been investigated at the protein level using both enzymic activity [2, 31, 33, 341 and reactivity with antibodies specific for either monomorphic or polymorphic NAT isoenzymes [2] . Polymorphic NAT is present in liver and gut, more specifically the duodenum 133, 341. Monomorphic NAT is present in all tissues, including the brain, although in the pineal gland the amount of monomorphic protein is below the detection of Western blotting [2] .
Investigation of transcription of polymorphic and monomorphic NAT in the livers of fast-acetylator rabbits shows that both polymorphic and nionomorphic NAT genes are transcribed as determined by amplification of cI)NA by pcr [31] , while in livers of slow-acetylator rabbits only monomorphic NAT cDNA can be detected. However, from Northern blot analysis, the amount of mRNA for the monomorphic NAT in slow acetylators would appear to be very low [31] , which may account for the low level of activity towards p-aminobenzoic acid observed with liver homogenates of slow-acetylator rabbits [31] . However, in previous studies [ 3 3 ] , it has been suggested that the activity of rabbit liver towards p-aminobenzoic acid did not appear to correlate with the acetylator phenotype determined with sulphamethazine. It may be that the level of expression of mRNA for monomorphic NAT varies among different slow-acetylating individual rabbits.
Comparison of liver cDNA and genomic clones of rabbit polymorphic NAT [ 18, 19, 30, 311 and monomorphic NAT [31] has shown that both the monomorphic and the polymorphic rabbit NAT have a 5' non-coding exon. This is different from the situation in humans where only the polymorphic enzyme has a non-coding exon. Therefore the mechanism controlling expression of monomorphic NA'I' in humans and rabbits may be different.
Humans
Although animal strains expressing fast and slow NAY' were established to act as models for polymorphic NA'I' in humans, investigation of NAT in the different species has served to emphasize that NA'I' polymorphism can arise through different mechanisms. In humans, two loci coding for NAT isoenzymes have been identified [ Fig. I] . A pseudogene has also been described [20] . The monomorphic and polymorphic NAT loci have been assigned to human chromosome 8 [20] . The monomorphic locus has so far appeared to be invariant among individuals. I Iowever, there are a range of alleles which have been identified at the polymorphic NAT locus. These are summarized in Fig. 1 . The differences among the slow-acetylator alleles in humans shows that the slow-acetylator phenotype in humans is not caused by a deletion but is due to a series of point mutations. some of which are associated with amino acid substitutions and some of which are not. The effects of these Human N-acetyltransferase Schematic diagram of genetic loci encoding human polymorphic (pnot) and monomorphic (mnot) arylamine NAT The distance between the two loci and the direction of the two genes is shown arbitrarily The filled regions denote exons The coding exons of both pnat and mnat are intronlessThe coding exon of pnat includes six bases before the start codon The non-coding exon of pnot is approx 8 kb upstream of the coding exon
The multiple alleles at the pnat locus encode for either fast or slow allotypic variants of NAT The S alleles differ from the F allele at up t o three point mutations nlorphic enzyme the other catalysed by the polymorphic enzyme. The polymorphic enzyme and the point mutations still have to be assessed fully, but from studies of the amount of NAT protein present in slow-acetylator livers compared with fast-acetylator livers it appears that there is less protein in slow-acetylator livers 1401. The cause of the reduction in the amount of protein could be either that less protein is being produced or that the protein being produced is then degraded. From studies with a transient expression system in eukaryotic cells, and constructs of combinations of fast and slow alleles, it appears that there may be differences among the alleles in the mechanism of generation of the slow-acetylator phenotype [MI. The slowacetylator allele corresponding to S l b (with point mutations at bases 341 and 4X1), appears to generate an unstable RNA while the allele S 2 (with mutations at bases 282 and 590) appears to generate an unstable protein. It is important to study these allotypic variants in vi7io and to this end, the use of cultured cells expressing different NAT alleles would be particularly helpful.
W e have therefore investigated the NAT genotype of the IIepG2 cell line which is a human hepatoma cell line. Determination of the genotype of HepG2 cells, using the method illustrated in Fig.   2 , has identified that these cells are of the slowacetylator genotype S l a , S2.
Tissue-specific expression
Investigation of NAT enzymic activity with 'polymorphic' and 'monomorphic' substrates has shown lize sulphamethazine, although they do metabolize p-aminobenzoic acid. However, these cells are the slow-acetylator genotype S l a , S 2 . The cultured monocytic cell line 11937 is an S l a , S l a homozygous cell line [20] and measurement of enzymic activity also showed that these cells will acetylate p-aminobenzoic acid but will not acetylate sulphamethazine [42] . 1Jsing cDNA from HepG2 and 17037 cells as a template for specific amplification by pcr of either monomorphic NA'I' or polymorphic NAT alleles, it has been demonstrated that in 17037 cells only monomorphic NAT and not polymorphic NAT mRNA is present (Table 1) . Changing 11937 cells to a more macrophage-like morphology by phorbol ester treatment does not induce the expression of mRNA for polymorphic NAT. Polymorphic NAT alleles are, however, transcribed in the tIepC2 cell line and other hepatotoma cell lines which have been tested. Although it must be borne in mind that these cells are transformed, these results would suggest that the polymorphic enzyme is expressed in hepatocytes in human liver, rather than in Kuppfer cells, as has been suggested (441.
Clues to the mechanism of control of the expression of monomorphic and polymorphic human NAT have come from comparison of genomic and cDNA clones for monomorphic and polymorphic NAT [ 17, 20, 211 . The upstream noncoding region of monomorphic NAT is the same in cDNA and genomic DNA clones. In contrast, polymorphic NAT cDNA clones and genomic DNA clones differ in the upstream region. Indeed, monomorphic genes are intronless in the coding region, the polymorphic locus in humans has a single intron in the non-coding region (Fig. 1) .
I992
Monomorphic NAT in humans has a widespread tissue distribution, including red blood cells,
Introduction
'I'remendous idwinces have been made w ithin the last decade in our knowledge of the cellular and molecular endocrinology of hormone-responsive carcinogenesis. pilrticularly breast cancer. Hoth homiones and 1iormone-indirc.ible autocrine growth factors play a prominent role in the mechanisms rnediating the growth of this important neoplasm of the reproductive system. I n fjict most breast cancers probably rely t o some degree upon oestrogen, oestrogen-inducible growth factors and/or prolactin for their growth [ 1, 21. hlelatonin, the m;i.ior secretory product of the rnammalian pineal gland, is an important neuroendocrine regulator of reproductive physiology in many mammalian species. In R number of these species including the rat, this indoleamine inhibits the development and growth of the normal repro- suggesting that NhlIl-induced breast cancers exhibit a circadian rhythm of sensitivity t o the oncostatic effects of this indole;imine.
I'inealectoniy, which effectively removes the endogenous melatonin signal, appears t o stimulate NMIT-induced mammary carcinogenesis t o some degree [ ( I ] . In contrast with the situation in pinealint;ict rats, morning treatments with melatonin in pinealectomized animals are effective in suppressing tuniour growth. It is interesting to note, however, that afternoon melatonin iniections are still more effective than morning injections in inhibiting carcinogenesis in pinealectomized animals 11 11.
These results point t o the possibility that the endogenous melatonin signal itself may act as an internal synchronizer of the endogenous rhythm(s) of tumour sensitivity to the oncostatic action of melatonin. It is tempting t o speculate that this response may involve circadian alterations in the number and/or affinity of melatonin binding sites which w~e have detected in crude membrane preparations of NMIT-induced rat mammary adenocarcinomas 1'21.
